Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors

European Journal of Pharmacology

Volumn 301, Issue 1-3, 1996, Pages

  Lahti, Robert A ^a   Mutin, Alex ^a   Cochrane, Erika V ^a   Tepper, Pieter G ^b   Dijkstra, Durk ^b   Wikström, Håkan ^b   Tamminga, Carol A ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Dopamine hD21 receptor; Dopamine hD4.4 receptor; Intrinsic activity

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; EMONAPRIDE; GUANOSINE TRIPHOSPHATE; PRECLAMOL; PROPYLNORAPOMORPHINE; RACLOPRIDE; RADIOLIGAND; RECEPTOR SUBTYPE; ROTIGOTINE; U 86170; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA;

AMINOQUINOLINES; ANIMALS; CELL MEMBRANE; CHO CELLS; CRICETINAE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HUMANS; PIPERIDINES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SALICYLAMIDES;

EID: 0029972880     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00127-6     Document Type: Article

References (8)

1. Baldessarini, R.J., A. Campbell, R. Booth and J.L. Neumeyer, 1991, S (+) Aporphines as potential limbic-selective antipsychotic agents, Schizophrenia Res. 4, 312.
2. Civelli, O., J.R. Bunzow, D.K. Grandy, Q.-Y. Zhou and H.H.M. Van Tol, 1991, Molecular biology of the dopamine receptors, Eur. J. Pharmacol. 207, 277.
3. 2 G protein-coupled receptor: utilization of receptor binding affinities, Mol. Pharmacol. 42, 432.
4. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications, Eur. J. Pharmacol. 236, 483.
5. Tamminga, C.A., M.H. Schaffer, R.C. Smith and J.M. Davis, 1978, Schizophrenic symptoms improve with apomorphine, Science 200, 567.
6. Tamminga, C.A., A.C. Lahti, R.A. Lahti and A. Carlsson, 1994, The evaluation of (-)-3-PPP, Preclamol, in schizophrenia, CINP Meeting 1994. Neuropsychopharmacology 10, Suppl. 1, 121S.
7. Timmerman, W., P.G. Tepper, B.G.J. Bohus and A.S. Horn, 1989, The potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437, Eur. J. Pharmacol. 181, 253.
8. 4 receptor with high affinity for the antipsychotic clozapine, Nature 350, 610.